The Supreme Court has spoken: A jury’s $70 million award to a man who developed gynecomastia while taking Risperdal as a child will stand. Johnson & Johnson took the case to the highest court in the land after losing the initial case and an appeal.
The case was brought by Adam Yount. Yount was put on Risperdal at age four and began developing breast tissue by age five. According ...
continue reading...
After having his $1.75 million compensatory Risperdal verdict reduced to just $680,000, plaintiff Nicholas Murray thought that was the end of his legal battle against the company whose misconduct, he claimed, had caused him to form female breast tissue. That was when a Pennsylvania Superior Court judge